Trials / Completed
CompletedNCT01511874
Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- HanAll BioPharma Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate efficacy and safety of ELIGARD 22.5mg in the treatment of subjects with prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ELIGARD 22.5mg | a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2013-05-01
- Completion
- 2013-12-01
- First posted
- 2012-01-19
- Last updated
- 2015-09-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01511874. Inclusion in this directory is not an endorsement.